Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 5,370,000 shares, an increase of 6.8% from the May 31st total of 5,030,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is presently 4.2 days.
Wall Street Analyst Weigh In
ABUS has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Thursday, June 6th. JMP Securities restated a “market outperform” rating and set a $4.00 target price on shares of Arbutus Biopharma in a research report on Thursday, April 4th. Finally, Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of Arbutus Biopharma in a research report on Wednesday, June 5th.
Get Our Latest Stock Analysis on Arbutus Biopharma
Institutional Inflows and Outflows
Arbutus Biopharma Stock Up 1.0 %
ABUS stock opened at $3.12 on Tuesday. Arbutus Biopharma has a twelve month low of $1.69 and a twelve month high of $3.64. The stock has a market capitalization of $588.80 million, a price-to-earnings ratio of -7.09 and a beta of 1.98. The firm’s fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $2.76.
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative return on equity of 62.68%. As a group, equities research analysts expect that Arbutus Biopharma will post -0.39 EPS for the current year.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Articles
- Five stocks we like better than Arbutus Biopharma
- Investing in the High PE Growth Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- The 3 Best Fintech Stocks to Buy Now
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Best Aerospace Stocks Investing
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.